Artios Pharma in Cambridge is steering a fresh initiative to fight ovarian cancer.
The company is pioneering the development of novel small molecule therapeutics that target the DNA damage response (DDR) process to treat patients with a broad range of cancers – but the new mission is special even by its own uncompromising standards.
Artios has triggered a randomised, Phase 2 expansion cohort in the ongoing Phase 1/2 trial evaluating its ataxia telangiectasia and Rad3-related (ATR) Inhibitor, ART0380, in combination with gemcitabine for the treatment of platinum resistant ovarian cancer.
To read more: https://www.businessweekly.co.uk/posts/artios-pharma-steps-up-ovarian-cancer-fight